<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During a six year period 43 patients with <z:e sem="disease" ids="C0010346" disease_type="Disease or Syndrome" abbrv="">Crohns disease</z:e> were included in a double-blind controlled trial of sulphasalazine given for one year as a possible treatment for reducing the relapse rate after resection or in asymptomatic patients with established disease </plain></SENT>
<SENT sid="1" pm="."><plain>No trend in favour of sulphasalazine over the control group was observed </plain></SENT>
<SENT sid="2" pm="."><plain>The difficulties of such a trial due to the small number of patients entered from nine hospitals, the varied nature of the disease, and the high incidence of complications, such as intraperitoneal <z:mpath ids='MPATH_612'>abscess</z:mpath> formation, are discussed </plain></SENT>
</text></document>